![CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial - The Lancet Oncology CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/2001025641/2003896921/gr1.gif)
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial - The Lancet Oncology
![Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer - ScienceDirect Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1365182X15311230-gr1.jpg)
Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer - ScienceDirect
![Further evidence of the prognostic role of pretreatment levels of CA 19-9 in advanced pancreatic cancer Further evidence of the prognostic role of pretreatment levels of CA 19-9 in advanced pancreatic cancer](http://old.scielo.br/img/revistas/ramb/v56n1/10t01.gif)
Further evidence of the prognostic role of pretreatment levels of CA 19-9 in advanced pancreatic cancer
![Median overall survival according to CA 19-9 serum level baseline level. | Download Scientific Diagram Median overall survival according to CA 19-9 serum level baseline level. | Download Scientific Diagram](https://www.researchgate.net/publication/240307282/figure/fig1/AS:216448275357696@1428616698105/Median-overall-survival-according-to-CA-19-9-serum-level-baseline-level.png)
Median overall survival according to CA 19-9 serum level baseline level. | Download Scientific Diagram
![Decreased serum carbohydrate antigen 19–9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients | BMC Cancer | Full Text Decreased serum carbohydrate antigen 19–9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-019-5460-4/MediaObjects/12885_2019_5460_Fig1_HTML.png)
Decreased serum carbohydrate antigen 19–9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients | BMC Cancer | Full Text
![Serum CA 19-9 and CA 125 as a diagnostic marker in carcinoma of gallbladder Bind MK, Mishra RR, Kumar V, Misra V, Singh PA - Indian J Pathol Microbiol Serum CA 19-9 and CA 125 as a diagnostic marker in carcinoma of gallbladder Bind MK, Mishra RR, Kumar V, Misra V, Singh PA - Indian J Pathol Microbiol](https://www.ijpmonline.org/articles/2021/64/1/images/IndianJPatholMicrobiol_2021_64_1_65_306520_t2.jpg)
Serum CA 19-9 and CA 125 as a diagnostic marker in carcinoma of gallbladder Bind MK, Mishra RR, Kumar V, Misra V, Singh PA - Indian J Pathol Microbiol
Definitive Characterization of CA 19-9 in Resectable Pancreatic Cancer Using a Reference Set of Serum and Plasma Specimens | PLOS ONE
![The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal - Ballehaninna - Journal of Gastrointestinal Oncology The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal - Ballehaninna - Journal of Gastrointestinal Oncology](https://cdn.amegroups.cn/journals/pbpc/files/journals/1/articles/181/public/181-PB15-4535-R1.png/w300)
The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal - Ballehaninna - Journal of Gastrointestinal Oncology
![Frontiers | Value of Carbohydrate Antigen 19-9 in Predicting Response and Therapy Control in Patients with Metastatic Pancreatic Cancer Undergoing First-Line Therapy Frontiers | Value of Carbohydrate Antigen 19-9 in Predicting Response and Therapy Control in Patients with Metastatic Pancreatic Cancer Undergoing First-Line Therapy](https://www.frontiersin.org/files/Articles/52319/fonc-03-00155-HTML/image_m/fonc-03-00155-g002.jpg)
Frontiers | Value of Carbohydrate Antigen 19-9 in Predicting Response and Therapy Control in Patients with Metastatic Pancreatic Cancer Undergoing First-Line Therapy
![Elevated serum CA 19-9 levels in patients with pulmonary nontuberculous mycobacterial disease | The Brazilian Journal of Infectious Diseases Elevated serum CA 19-9 levels in patients with pulmonary nontuberculous mycobacterial disease | The Brazilian Journal of Infectious Diseases](https://multimedia.elsevier.es/PublicationsMultimediaV1/item/multimedia/S1413867015001944:gr1.jpeg?xkr=ue/ImdikoIMrsJoerZ+w9/qSCRz5Ib+l7k+w1jVIYLy+x9hT2kumM6W8qgi/U+qBd+ZSkUVK08WrCDiDbtm65hxkhZgGpPQisVcmJ0bBAPSPJ2ulzFXXEVU664x8w0rUdsCt8+ziC4W6uwiWGgy5aRsctuEgkMfMpDPPPfXhpSFn4PLd/p8Mn0Xqkk3GZUx2e8tYOBbaLrQw2o8CAxQJxTD2uJp6rFIgsXR+EoSkcjNPWyYBqe4ZZYLnB94b8HFaidTDDrm+IoHxVey9ptGXBbtUYGP1cW38DF10I67YRMw=)
Elevated serum CA 19-9 levels in patients with pulmonary nontuberculous mycobacterial disease | The Brazilian Journal of Infectious Diseases
![Causative conditions of elevated CA 19-9 levels in the elevated CA 19-9... | Download Scientific Diagram Causative conditions of elevated CA 19-9 levels in the elevated CA 19-9... | Download Scientific Diagram](https://www.researchgate.net/publication/332276704/figure/tbl2/AS:745471622524930@1554745693160/Causative-conditions-of-elevated-CA-19-9-levels-in-the-elevated-CA-19-9-group-n581.png)
Causative conditions of elevated CA 19-9 levels in the elevated CA 19-9... | Download Scientific Diagram
Clinical Significance and Revisiting the Meaning of CA 19-9 Blood Level Before and After the Treatment of Pancreatic Ductal Adenocarcinoma: Analysis of 1,446 Patients from the Pancreatic Cancer Cohort in a Single
![Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases | Scientific Reports Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases | Scientific Reports](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-020-65720-8/MediaObjects/41598_2020_65720_Fig3_HTML.png)
Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases | Scientific Reports
![Patients with normal‑range CA19‑9 levels represent a distinct subgroup of pancreatic cancer patients Patients with normal‑range CA19‑9 levels represent a distinct subgroup of pancreatic cancer patients](https://www.spandidos-publications.com/article_images/ol/13/2/ol-13-02-0881-g00.jpg)